Occudo Quantitative Strategies LP Takes $911,000 Position in ICU Medical, Inc. (NASDAQ:ICUI)

Occudo Quantitative Strategies LP purchased a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the 4th quarter, Holdings Channel.com reports. The fund purchased 5,870 shares of the medical instruments supplier’s stock, valued at approximately $911,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ICUI. Harvest Fund Management Co. Ltd purchased a new position in ICU Medical in the 4th quarter valued at about $33,000. Quarry LP increased its position in shares of ICU Medical by 764.3% during the fourth quarter. Quarry LP now owns 242 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 214 shares during the last quarter. Murphy & Mullick Capital Management Corp acquired a new position in shares of ICU Medical in the fourth quarter worth about $52,000. Venturi Wealth Management LLC lifted its stake in shares of ICU Medical by 64.0% in the fourth quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier’s stock worth $82,000 after acquiring an additional 206 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in ICU Medical by 88.8% in the fourth quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ICUI. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Tuesday, April 8th. KeyCorp decreased their price target on shares of ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a research report on Monday, April 21st. Raymond James dropped their price target on shares of ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating for the company in a research note on Friday, May 9th. Finally, StockNews.com downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a research note on Saturday. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $192.67.

Insider Activity at ICU Medical

In other ICU Medical news, Director David C. Greenberg sold 1,942 shares of ICU Medical stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $143.66, for a total value of $278,987.72. Following the completion of the transaction, the director now owns 6,760 shares of the company’s stock, valued at $971,141.60. The trade was a 22.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 1.50% of the company’s stock.

ICU Medical Stock Down 0.5%

NASDAQ:ICUI opened at $143.59 on Wednesday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The company has a market capitalization of $3.53 billion, a price-to-earnings ratio of -31.42 and a beta of 0.87. ICU Medical, Inc. has a one year low of $100.91 and a one year high of $196.26. The stock has a 50-day simple moving average of $140.71 and a 200 day simple moving average of $154.69.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.49. The company had revenue of $599.49 million for the quarter, compared to the consensus estimate of $574.15 million. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. ICU Medical’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.96 EPS. Sell-side analysts predict that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.